Seres Therapeutics' (MCRB) CEO Roger Pomerantz on Q3 2018 Results - Earnings Call Transcript [Seeking Alpha]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Seeking Alpha
Seres Therapeutics, Inc. (NASDAQ: MCRB ) Q3 2018 Earnings Conference Call November 8, 2018 8:30 AM ET Executives Carlo Tanzi - VP, IR & Corporate Communications Roger Pomerantz - President, CEO & Chairman Eric Shaff - Chief Operating & Financial Officer David Cook - CSO Analysts Holly Barra - Goldman Sachs David Huang - Canaccord Operator Hello and welcome to the Seres Therapeutics Q3 2018 Earnings Conference Call. At this time, all participants are in a listen only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference is being recorded. And now I would like to introduce your host for today's call, Dr. Carlo Tanzi, Vice President, Investor Relations and Corporate Communications. Sir, you may begin. Carlo Tanzi Thank you and good morning. A press release with the company's third quarter 2018 financial results and a business update became available at 7 a.m. Eastern Time
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $5.00 to $4.00. They now have an "outperform" rating on the stock.MarketBeat
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its price target lowered by analysts at Chardan Capital from $8.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023) [Yahoo! Finance]Yahoo! Finance
- World $2.5 Bn Human Microbiome Market Trends, Forecasts and Competitive Analysis 2018-2023 and 2024-2030 [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 5/8/24 - Beat
MCRB
Sec Filings
- 5/8/24 - Form 10-Q
- 5/8/24 - Form 8-K
- 5/7/24 - Form 8-K
- MCRB's page on the SEC website